Benefit of dapagliflozin when used with cardiovascular medications in patients with type 2 diabetes
Slomski A
JAMA. 2022;328(9):817.
Leggi
Breaking news
Risk of adverse events with liraglutide in HFrEF: a post‐hoc analysis of the FIGHT trial
Neves JS, Vasques-Nóvoa F, Borges-Canha M, et al.
Diabetes Obes Metab. Pub. online 9 Sep 2022.
Leggi
Mean HbA1c and HbA1c variability are associated with differing diabetes-related complications in patients with type 2 diabetes mellitus
Wu TE, Su YW, Chen HS
Diabetes Res Clin Pract. 2022;110069.
Leggi
Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre® system initiation in people with type 2 diabetes on basal insulin therapy in France
Guerci B, Roussel R, Levrat-Guillen F, et al.
Diabetes Technol Ther. Pub. online 12 Sep 2022.
Leggi
Effect of a comprehensive telehealth intervention vs telemonitoring and care coordination in patients with persistently poor type 2 diabetes control: a randomized clinical trial
Crowley MJ, Tarkington PE, Bosworth HB, et al.
JAMA Intern Med. 2022;182(9):943-952.
Leggi
Large effect size in composite kidney outcomes than in majors cardiovascular events of SGLT2 inhibitors compared with GLP-1 RAs: a pooled analysis of type 2 diabetes trials
Diallo A, Carlos-Bolumbu M, Renard E, Galtier F
Diabetes Obes Metab. Pub. online 3 Sep 2022.
Leggi
Empagliflozin in acute myocardial infarction: the EMMY trial
von Lewinski D, Kolesnik E, Tripolt NJ, et al.
European Heart Journal. 2022;ehac494.
Leggi
Closed-loop therapy and preservation of c-peptide secretion in type 1 diabetes
Boughton CK, Allen JM, Ware J, et al.
N Engl J Med. 2022;387:882-893.
Leggi
Estimated event-free survival benefits with dapagliflozin in hf with mildly reduced or preserved ejection fraction
Vaduganathan M, Claggett BL, Jhund P et, al.
J Am Coll Cardiol. 2022;S0735-1097(22)06611-6
Leggi
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Vaduganathan M, Docherty KF, Claggett BL, et al.
Lancet. 2022 Aug 26;S0140-6736(22)01429-5
Leggi